Abstracts Archive - Page 895 of 2607 - ACR Meeting Abstracts

Abstract Number: 0879 • ACR Convergence 2020
Application of Treat-to-Target in Axial Spondyloarthritis in Daily Practice
Esther Beckers¹, Annelies Boonen¹, Casper Webers¹, Peter Ten Klooster², Harald Vonkeman², Monique Efde³ and Astrid van Tubergen⁴, ¹Maastricht University Medical Center, Maastricht, Netherlands, ²University of Twente, Enschede, Netherlands, ³VieCuri Medical Center, Venlo, Netherlands, ⁴Maastricht University Medical Center, Maastricht
Background/Purpose: Treat-to-target (T2T) management strategies in inflammatory rheumatic diseases aim to prevent damage and improve overall functioning and health by treating patients towards a predefined…
Abstract Number: 0880 • ACR Convergence 2020
Ixekizumab Improves Signs and Symptoms of Patients with Radiographic and Non-radiographic Axial Spondyloarthritis and Extra-articular Manifestation of Enthesitis Through 16 Weeks
Georg Schett¹, Filip Van den Bosch², Xenofon Baraliakos³, David Sandoval⁴, Vladimir Geneus⁴, Rebecca Bolce⁴, Soyi Liu-Leage⁵, Andris Kronbergs⁴ and Philip Mease⁶, ¹Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ²Ghent University Hospital, Ghent, Belgium, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ⁴Eli Lilly and Company, Indianapolis, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Axial SpA (axSpA) is a chronic inflammatory disease affecting the spine and sacroiliac (SI) joints and has two subtypes that represent the spectrum of…
Abstract Number: 0881 • ACR Convergence 2020
Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis During Certolizumab Pegol Treatment: 96-Week Results from the C-VIEW Study
Irene van der Horst-Bruinsma¹, Rianne van Bentum¹, Frank Verbraak², Thomas Rath³, James Rosenbaum⁴, Bengt Hoepken⁵, Oscar Irvin-Sellers⁶, Thomas Kumke⁵, Lars Bauer⁵ and Martin Rudwaleit⁷, ¹Department of Rheumatology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, ²Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, ³St Franziskus-Hospital, Münster, Germany, ⁴Oregon Health & Science University, Portland, OR, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Slough, United Kingdom, ⁷Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany
Background/Purpose: Acute anterior uveitis (AAU) is the most common extra-articular manifestation in axial spondyloarthritis (axSpA), affecting up to 40% of patients and causing significant burden.1…
Abstract Number: 0882 • ACR Convergence 2020
Efficacy and Safety of Secukinumab in Patients with Spondyloarthritis and Enthesitis at the Achilles Tendon: 52-weeks Results from a Randomized, Placebo-controlled Phase 3b Trial
Frank Behrens¹, Philipp Sewerin², Eugenio De Miguel³, Yusuf Patel⁴, Anastas Batalov⁵, Eva Dokoupilova⁶, Christine Kleinmond⁷, Effie Pournara⁸, Ankita Shekhawat⁹, Claudia Jentzsch¹⁰, Annette Wiedon¹¹ and Xenofon Baraliakos¹², ¹CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, ²Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf, Duesseldorf, Germany, ³Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁴Hull University Teaching Hospitals, Hull East Yorkshire, United Kingdom, ⁵Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, ⁶MEDICAL PLUS s.r.o., Uherske Hradiste, University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Uherské Hradiště, Czech Republic, ⁷ClinProject GmbH, Eurasburg, Germany, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Healthcare Private Limited, Hyderabad, Telangana, India, ¹⁰Novartis Pharma GmbH, Nuremberg, Germany, ¹¹Novartis Pharma GmbH, Nurnberg, Germany, ¹²Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany
Background/Purpose: Enthesitis is a key feature of all types of spondyloarthritis (SpA) that substantially contributes to the overall burden of disease. Inhibition of the key…
Abstract Number: 0883 • ACR Convergence 2020
Network Meta-Analysis of Long-Term Efficacy (ASAS40) of Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in bDMARD-Naïve Patients with Non-Radiographic Axial Spondyloarthritis
Sandeep Kiri¹, Mindy Kim², Marissa Betts³, Madhura Chitnis³, Kyle Fahrbach³, Jialu Tarpey³ and Monica Turner³, ¹UCB Pharma, Slough, England, United Kingdom, ²UCB Pharma, Smyrna, GA, ³Evidera, Waltham
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) have demonstrated large clinical improvements in patients with non-radiographic axial spondyloarthritis (nr-axSpA), with patients naïve to bDMARDs experiencing substantial…
Abstract Number: 0884 • ACR Convergence 2020
Comparison of Disease Control Thresholds in Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Philip Mease¹, Robert McLean², Taylor Blachley², Laura Anatale-Tardiff³, Christopher Saffore⁴, Patrick Zueger⁴ and Alexis Ogdie⁵, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Waltham, ⁴AbbVie Inc., North Chicago, IL, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: There is no single accepted measure of low/minimal disease activity (LDA/MDA) for patients with PsA; thus, describing the characteristics of real-world patients meeting different…
Abstract Number: 0885 • ACR Convergence 2020
Impact of HLA-B27 Status on Clinical Outcomes in Patients with Ankylosing Spondylitis Treated with Secukinumab
Atul Deodhar¹, Philip Mease², Denis Poddubnyy³, Vibeke Strand⁴, Paula Machado⁵, Abhijit Shete⁶, Xiangyi Meng⁵ and Marina Magrey⁷, ¹Oregon Health & Science University, Portland, OR, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁴Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Ankylosing spondylitis (AS) is strongly associated with the genetic marker HLA-B27. In patients with AS, negative HLA-B27 status is a predictor of worse response…
Abstract Number: 0886 • ACR Convergence 2020
Achievement of Partial Remission and Inactive Disease in Upadacitinib-Treated Patients with Ankylosing Spondylitis
Atul Deodhar¹, Andrew Östör², Anna Maniccia³, Fabiana Ganz⁴, Tianming Gao³, Alvina D. Chu⁵ and Denis Poddubnyy⁶, ¹Oregon Health & Science University, Portland, OR, ²Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Inc., Baar, Switzerland, ⁵AbbVie, North Chicago, IL, ⁶Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Assessment of SpondyloArthritis international Society (ASAS) response criteria and AS Disease Activity Score (ASDAS) are both commonly used, rigorous composite indices consisting of components…
Abstract Number: 0887 • ACR Convergence 2020
Increasing Use of Biologics in Treatment of Systemic Lupus Erythematosus Patients in US Clinical Practice: Real-World Observations from Trio Health and the American Rheumatology Network
Simon Helfgott¹, Jeremy Broestl², Kent Kwas Huston³, Deepali Rane², Jasvinder Singh⁴, Nehad Soloman⁵ and Colin Edgerton⁶, ¹BWH- HMS, Boston, MA, ²Trio Health, Louisville, CO, ³Kansas City Physician Partners, Kansas City, MO, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ⁶Articularis Healthcare, Summerville, SC
Background/Purpose: Systemic lupus erythematosus (SLE) treatments include steroids, antimalarials, immunosuppressants and/or biologics, though the use of biologics has been reported as minimal in claim-based studies…
Abstract Number: 0888 • ACR Convergence 2020
Guselkumab Efficacy and Safety in TNF-Inhibitor-Experienced and TNF-Inhibitor-Naïve Patients with Active PsA: 1-Year Results of a Phase 3, Randomized, Controlled Study
Christopher Ritchlin¹, Atul Deodhar², Wolf-Henning Boehncke³, Enrique Soriano⁴, Elizabeth Hsia⁵, Alexa Kollmeier⁶, Xie Xu⁷, Federico Zazzetti⁸, May Shawi⁹, Yusang Jiang¹⁰, Shihong Sheng¹⁰, Prasheen Agarwal¹⁰ and Philip Helliwell¹¹, ¹Department of Medicine, University of Rochester Medical Center, Rochester, NY, ²Oregon Health & Science University, Portland, OR, ³Geneva University Hospitals, Geneva, Switzerland, ⁴Department of Public Health, Instituto Universitario, Escuela de Medicina Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Capital Federal, Buenos Aires, Argentina, ⁵Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁶Janssen Research & Development, LLC, La Jolla, CA, ⁷Janssen Research & Development, LLC, San Marcos, CA, ⁸Janssen Scientific Affairs, LLC, Buenos Aires, Argentina, ⁹Janssen Global Services, LLC, Toronto, ON, Canada, ¹⁰Janssen Research & Development, LLC, Spring House, PA, ¹¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Guselkumab (GUS), a novel anti-IL-23 monoclonal antibody specific to the IL-23p19-subunit, is approved to treat psoriasis. Through week (W) 24 of the Phase 3,…
Abstract Number: 0889 • ACR Convergence 2020
Efficacy of Secukinumab Treatment in Patients with Early Psoriatic Arthritis: A Pooled Analysis of 4 Phase 3 Studies
Christopher Ritchlin¹, Alan Kivitz², Peter Nash³, Renato Calheiros⁴, Xiangyi Meng⁵, Corine Gaillez⁶, Bruce Kirkham⁷ and Iain McInnes⁸, ¹Department of Medicine, University of Rochester Medical Center, Rochester, NY, ²Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ³School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁴Novartis Pharmaceuticals Corporation, Hoboken, NJ, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁸Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) can progress quickly and lead to irreversible damage within 2 years of initial assessment if not treated.1 Secukinumab (SEC), a selective…
Abstract Number: 0890 • ACR Convergence 2020
Ixekizumab Treatment Improves Fatigue, Spinal Pain, Stiffness, and Sleep in Patients with Nonradiographic Axial Spondyloarthritis
Philip Mease¹, Atul Deodhar², Proton Rahman³, Helena Marzo-Ortega⁴, Vibeke Strand⁵, Theresa Hunter⁶, David Adams⁷, David Sandoval⁶, Andris Kronbergs⁶, Baojin Zhu⁷, Ann Leung⁸, Soyi Liu-Leage⁷ and Victoria Navarro-Compán⁹, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ⁴The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ⁵Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁶Eli Lilly and Company, Indianapolis, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸Syneos Health, Morrisville, ⁹Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain
Background/Purpose: Common symptoms of axial spondyloarthritis (axSpA) include fatigue, spinal pain, stiffness, and sleep problems, which can impair health-related quality of life. Ixekizumab (IXE) treatment…
Abstract Number: 0891 • ACR Convergence 2020
Four-Year Efficacy and Safety of Guselkumab in Psoriasis Patients with and Without Psoriatic Arthritis: A Pooled Analysis from VOYAGE 1 and VOYAGE 2
Kristian Reich¹, Jan Dutz², Peter Foley³, Diamant Thaçi⁴, Ron Vender⁵, Michael Song⁶, Megan Miller⁶, Yin Yu⁶, Shu Li⁷, Yaung-Kaung Shen⁶ and April W. Armstrong⁸, ¹Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation®, Hamburg, Germany, ²Vancouver General Hospital, Vancouver, Canada, ³University of Melbourne, St. Vincent’s Hospital, Melbourne and Skin & Cancer Foundation Inc, Carlton, Australia, ⁴Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁵McMaster University, Hamilton, Canada, ⁶Janssen Research & Development, LLC, Spring House, ⁷Janssen Scientific Affairs, LLC, Horsham, ⁸Keck School of Medicine of University of Southern California, Los Angeles, CA
Background/Purpose: Guselkumab (GUS), a fully human monoclonal antibody, selectively binds and blocks IL-23. VOYAGE 1 and VOYAGE 2 are two ongoing Phase 3, randomized, double-blind,…
Abstract Number: 0892 • ACR Convergence 2020
Long-Term Safety Profile of Ixekizumab Treatment in Patients with Axial Spondyloarthritis
Sergio Schwartzman¹, David Sandoval², Andris Kronbergs², Jeffrey Lisse³, Himanshu Patel³, Wen Xu³, Soyi Liu-Leage³, Marina Magrey⁴, Helena Marzo-Ortega⁵ and Denis Poddubnyy⁶, ¹Weill Cornell Medical College, New York, NY, ²Eli Lilly and Company, Indianapolis, ³Eli Lilly and Company, Indianapolis, IN, ⁴Case Western Reserve University School of Medicine, Cleveland, OH, ⁵The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ⁶Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, has demonstrated efficacy in the treatment of the axial spondyloarthritis (axSpA) spectrum (ankylosing spondylitis and…
Abstract Number: 0893 • ACR Convergence 2020
Is It Feasible to Achieve Recommended Therapeutic Target Objective in Patients with Axial Spondyloarthritis in Clinical Practice? Data from the SpA-paz Cohort
Karen Franco Gomez¹, Chaimada Plasencia-Rodriguez¹, Marta Novella Navarro¹, Diego Benavent Nunez¹, Patricia Bogas¹, Romina Nieto², Irene Monjo³, Laura Nuño¹, Alejandro Villalba⁴, Diana Peiteado¹, Alejandro Balsa-Criado¹ and Victoria Navarro-Compán⁵, ¹HOSPITAL UNIVERSITARIO LA PAZ, MADRID, Spain, ²hospital intendente carrasco, Rosario, Argentina, ³Rheumatology, La Paz University Hospital- IdiPAZ, Madrid, Spain, ⁴Hospital La Paz - IdiPAZ, Madrid, Spain, ⁵Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain
Background/Purpose: to analyze the frequency of patients with axSpA achieving maintained remission (R) or low disease activity (LDA) after receiving biological therapy. Secondary objectives included:…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].